HOXD13驱动黑色素瘤血管生成与免疫逃逸的可靶向发育程序
该研究比较早期黑色素瘤、痣及其他肿瘤的转录因子表达,发现同源域转录因子HOXD13在黑色素瘤中上调并驱动类黑色素母细胞程序,与血管生成和免疫细胞排斥强相关。通过转录组学、3D染色质谱和体内模型,HOXD13通过增强子-启动子接触激活VEGFA、SEMA3A和NT5E(CD73),重塑血管并升高免疫抑制性腺苷;联合VEGFR和腺苷受体抑制可逆转HOXD13诱导的肿瘤生长。
要点
- HOXD13在黑色素瘤中上调,驱动类黑色素母细胞程序并与血管生成及免疫排斥相关。
- HOXD13通过3D增强子-启动子接触激活VEGFA、SEMA3A和NT5E(CD73)。
- 联合VEGFR和腺苷受体抑制可逆转HOXD13诱导的肿瘤生长。
核心结论
- HOXD13驱动同时促进血管生成和免疫抑制的发育程序,是黑色素瘤的潜在治疗靶点。
研究设计与样本
- 比较早期黑色素瘤、痣和其他癌症的转录因子表达。
- 采用转录组学、3D染色质谱分析和体内模型研究HOXD13功能。
主要发现
- HOXD13在黑色素瘤中上调,与血管生成和免疫细胞排斥强相关。
- HOXD13通过增强子-启动子接触激活VEGFA、SEMA3A和NT5E(CD73)表达。
- HOXD13促进血管重塑并升高免疫抑制性腺苷,增强肿瘤生长并抑制T细胞浸润。
关键数值与推荐
- 联合VEGFR和腺苷受体(AdR)抑制可逆转HOXD13诱导的肿瘤生长。
临床怎么用
- 针对HOXD13下游通路,联合VEGFR和腺苷受体抑制可能为黑色素瘤提供治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Ultraviolet-induced DNA mutations generate genetic drivers of cutaneous melanoma and numerous neoantigens that can trigger antitumor immunity. Melanoma cells must therefore rapidly evade immune detection by modulating cell-autonomous epigenetic mechanisms and tumor-microenvironment interactions. Although angiogenesis typically facilitates immune infiltration, solid tumors increase vascularization while limiting immune cell entry. By comparing transcription factor (TF) expression across early-stage melanoma, nevi, and other cancers, we found that the homeodomain TF HOXD13 drives a melanoblast-like program upregulated in melanoma and strongly correlated with angiogenesis and immune cell exclusion. Using transcriptomics, 3D chromatin profiling, and in vivo models, we show that HOXD13 promotes tumor growth by enhancing angiogenesis and suppressing T-cell infiltration. HOXD13 orchestrates 3D enhancer-promoter contacts activating VEGFA, SEMA3A, and NT5E (CD73), which remodel vasculature and elevate immunosuppressive adenosine. Consistently, HOXD13-induced tumor growth is reversed by combined VEGFR and adenosine receptor (AdR) inhibition, revealing a dual proangiogenic and immunosuppressive HOXD13 axis with therapeutic relevance. SIGNIFICANCE: Immune evasion contributes to cancer progression and poor response to immunotherapy. We report a novel epigenetic mechanism led by the TF HOXD13, allowing melanoma cells to simultaneously inhibit and exclude T cells, which can be counteracted therapeutically using VEGF and AdR inhibitors.
引用
- Berico P, Flores Yanke A, Vand-Rajabpour F, et al. A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma. Cancer Discov. 2026. PMID: 41631877. doi:10.1158/2159-8290.CD-24-1853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。